Researchers find a protein that controls cell growth

March 10, 2004

Researchers at New York University School of Medicine have found that a protein called APC plays a role in controlling a web of molecular interactions that can transform normal cells into cancerous ones. The finding may provide new possibilities for devising cancer therapies that target this protein.

"A tumor cell lacks the ability to limit its own growth," says Michele Pagano, M.D., Associate Professor of Pathology, who led the new study published in the March 11 issue of Nature. "APC puts the brake on cell growth."

The study sheds light on the relationship between APC and two other proteins involved in the development of cancer -- Skp2 and p27. APC controls the abundance of Skp2, according to the study. Skp2 determines whether a cell will begin the process of making copies of itself, and it was previously tied to p27.

"This is a very important and exciting study," says Avram Hershko, M.D., Ph.D., Distinguished Professor at Technion-Israel Institute of Technology in Haifa, who has made seminal contributions to understanding protein degradation and the cell cycle, the sequence of events a cell undergoes to make a copy of itself by dividing into two.

"Only recently has it been realized that Skp2 is a very important oncogene," Dr. Hershko explained in an e-mail. "Dr. Pagano's new study reveals how Skp2 itself is eliminated. This knowledge may be used in the future to down-regulate (decrease the activity of) Skp2 in cancers, and thus to arrest the growth of these cancers."

The gene encoding the p27 protein is one of about twenty so-called "tumors suppressor genes" that have been linked to cancer. When these genes aren't fully activated or are mutated, cells lose their ability to limit their own growth. In previous studies, low levels of the p27 protein have been associated with the development of certain tumors of the breast, colon, lung, esophagus, bone marrow, and thymus. In a sense, APC indirectly controls the abundance of p27.

In 1997, Dr. Pagano's group and other research teams separately reported that low levels of p27 correlated with a poor prognosis among patients with colorectal and breast cancers, regardless of tumor size. Since then, numerous reports have extended these original findings to many other types of tumors. In more recent studies, researchers have discovered that p27 and Skp2 were inversely correlated in certain tumors, so when Skp2 levels were high, p27 levels were low.

However, no one knew what controlled the cellular abundance of Skp2, which is now considered an oncogene. Alterations in oncogenes often lead to uncontrolled cell growth, and to cancer. Now, with this latest report in Nature, Dr. Pagano's group has figured out that levels of Skp2 are controlled by APC; APC actually induces the degradation of Skp2.

Although this seeming alphabet soup of protein acronyms can be confusing to lay people, these proteins are of utmost interest to cancer researchers because they play an essential role in the cell cycle.

Disruptions in the breakdown of proteins associated with the cell cycle can lead to cancer, the uncontrolled growth of cells. In normal cells, Skp2 needs to be degraded in order for the cell to remain in a quiescent, or resting, state. When it isn't degraded, its levels rise and then the cell is pushed into the initial stage of cell division, called the S phase, in which the cell synthesizes its DNA in preparation for replicating its genome.

In Dr. Pagano's latest study, his group demonstrated that cells with high levels of a mutated form of Skp2 promoted the degradation of p27. As a result, these cells entered the S phase of the cell cycle faster than control cells with unmutated Skp2.

The premature entry of a cell into the S phase is a potential cause of genetic instability, which in turn can propel a cell into uncontrolled proliferation, resulting in cancer. Dr. Pagano says that his laboratory plans to ascertain whether there are mutations in the gene encoding the APC protein that cause Skp2 to accumulate. (If APC were mutated, then the instructions for Skp2 degradation would be missing). If so, then perhaps drugs can be developed that counter these mutations in APC.

"An increase in the amount of Skp2 contributes to cancer development," says Dr. Pagano. "Since APC controls the cellular abundance of Skp2, we think that APC deregulation plays a role in the malignant transformation of cells. If we could find a way to decrease the levels of Skp2 or inhibit its activity -- possibly through manipulation of APC -- then we may be able to develop new cancer therapies."

The Warren, New Jersey-based biotechnology company Celgene Corp. has given Dr. Pagano's laboratory a grant to study the cellular function of some Skp2 homologs, which have similar sequences of amino acids, with the idea that this will lead to the identification of novel targets for cancer therapies. In addition, Dr. Pagano's lab and Celgene are collaborating on a project to screen for inhibitors of Skp2, and several inhibitors already have been identified.

The co-authors of the Nature study are Tarig Bashir, Ph.D.; N. Valerio Dorrello, M.D.; Virginia Amador, Ph.D.; and Daniele Guardavaccaro, Ph.D. They are all members of Dr. Pagano's laboratory.
-end-
The study was supported by numerous grants and fellowships, including two National Institute of Health grants to Dr. Pagano; a fellowship from the New York State Breast Cancer Research and Education fund to Dr. Bashir; a Human Frontiers Science Program fellowship to Dr. Amador; and an American-Italian Cancer Foundation fellowship and a Susan Komen Breast Cancer Foundation fellowship to Dr. Guardavaccaro.

NYU Langone Medical Center / New York University School of Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.